Vertex Pharmaceuticals (WBO:VRTX) Cyclically Adjusted Book per Share: €35.84 (As of Mar. 2026)


WBO:VRTX Vertex Pharmaceuticals Inc WBO:VRTX
91 GF Score
Price €435.40
GF Value €440.30
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Vertex Pharmaceuticals Cyclically Adjusted Book per Share?

Vertex Pharmaceuticals WBO:VRTX +0.52% 91 Cyclically Adjusted Book per Share is €35.84 as of Mar. 2026. GuruFocus rates WBO:VRTX with a GF Score™ of 91/100 and a GF Value™ of €440.30 (Fairly Valued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Vertex Pharmaceuticals's adjusted book value per share for the three months ended in Mar. 2026 was €65.895. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €35.84 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Vertex Pharmaceuticals's average Cyclically Adjusted Book Growth Rate was 23.10% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 26.70% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 31.70% per year. During the past 10 years, the average Cyclically Adjusted Book Growth Rate was 29.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Vertex Pharmaceuticals was 38.60% per year. The lowest was -7.70% per year. And the median was 7.15% per year.

As of today (2026-07-01), Vertex Pharmaceuticals's current stock price is €435.40. Vertex Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was €35.84. Vertex Pharmaceuticals's Cyclically Adjusted PB Ratio of today is 12.15.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Vertex Pharmaceuticals was 39.61. The lowest was 10.21. And the median was 18.06.


Vertex Pharmaceuticals  (WBO:VRTX) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Vertex Pharmaceuticals's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=435.40/35.84
=12.15

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Vertex Pharmaceuticals was 39.61. The lowest was 10.21. And the median was 18.06.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Vertex Pharmaceuticals Cyclically Adjusted Book per Share Related Terms


Vertex Pharmaceuticals Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Vertex Pharmaceuticals's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vertex Pharmaceuticals Cyclically Adjusted Book per Share Chart

Vertex Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 12.56 17.93 23.19 30.98 33.67

Vertex Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 31.22 30.26 31.57 33.67 35.84

WBO:VRTX vs REGN, ALNY, RVMD: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Vertex Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vertex Pharmaceuticals Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vertex Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Vertex Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.


WBO:VRTX
91GF Score
Vertex Pharmaceuticals Inc WBO:VRTX
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vertex Pharmaceuticals Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Vertex Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=65.895/330.2130*330.2130
=65.895

Current CPI (Mar. 2026) = 330.2130.

Vertex Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201606 3.526 241.018 4.831
201609 3.670 241.428 5.020
201612 4.416 241.432 6.040
201703 5.635 243.801 7.632
201706 5.931 244.955 7.995
201709 5.947 246.819 7.956
201712 6.769 246.524 9.067
201803 7.640 249.554 10.109
201806 9.021 251.989 11.821
201809 9.743 252.439 12.745
201812 15.278 251.233 20.081
201903 16.306 254.202 21.182
201906 17.481 256.143 22.536
201909 18.542 256.759 23.847
201912 21.146 256.974 27.173
202003 22.571 258.115 28.876
202006 25.669 257.797 32.880
202009 26.541 260.280 33.672
202012 27.475 260.474 34.831
202103 29.144 264.877 36.333
202106 29.458 271.696 35.803
202109 31.619 274.310 38.063
202112 35.125 278.802 41.602
202203 38.750 287.504 44.506
202206 44.094 296.311 49.139
202209 51.276 296.808 57.047
202212 51.101 296.797 56.854
202303 52.347 301.836 57.268
202306 55.389 305.109 59.946
202309 60.011 307.789 64.383
202312 62.559 306.746 67.345
202403 66.059 312.332 69.841
202406 53.197 314.175 55.913
202409 54.642 315.301 57.226
202412 60.992 315.605 63.815
202503 59.381 319.799 61.315
202506 58.102 322.561 59.480
202509 58.104 324.800 59.072
202512 62.760 324.054 63.953
202603 65.895 330.213 65.895

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of €35.84 mean?
Vertex Pharmaceuticals (WBO:VRTX) has a Cyclically Adjusted Book per Share of €35.84 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Vertex Pharmaceuticals and its competitors.
Is Vertex Pharmaceuticals' Cyclically Adjusted Book per Share too high?
Vertex Pharmaceuticals' current Cyclically Adjusted Book per Share is €35.84. Overall, Vertex Pharmaceuticals has a GF Score™ of 91/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Vertex Pharmaceuticals' Cyclically Adjusted Book per Share compare to REGN and ALNY?
Vertex Pharmaceuticals' Cyclically Adjusted Book per Share of €35.84 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Vertex Pharmaceuticals and its competitors. Vertex Pharmaceuticals's current Cyclically Adjusted Book per Share is €35.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vertex Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Vertex Pharmaceuticals (WBO:VRTX) is currently considered Fairly Valued. The stock's GF Value™ is €440.30, compared to a current price of €435.40 — trading 1.1% below its estimated fair value. The current Cyclically Adjusted Book per Share is €35.84. Vertex Pharmaceuticals' overall GF Score™ is 91/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Vertex Pharmaceuticals (WBO:VRTX), the current Cyclically Adjusted Book per Share is €35.84 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vertex Pharmaceuticals (WBO:VRTX) Overvalued in 2026?

Based on GuruFocus' analysis, Vertex Pharmaceuticals stock appears to be undervalued. The current stock price of €435.40 is trading 1.1% below its estimated GF Value™ of €440.30. GuruFocus considers Vertex Pharmaceuticals to be Fairly Valued.

Key valuation signals for WBO:VRTX:

  • Cyclically Adjusted Book per Share: €35.84
  • GF Value™: €440.30 vs. price of €435.40 (1.1% below fair value)
  • GF Score™: 91/100 with 4 warning signs

No single metric tells the full story. See the WBO:VRTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Vertex Pharmaceuticals Business Description

Address 50 Northern Avenue, Boston, MA, USA, 02210
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
91GF Score

Get the complete analysis for WBO:VRTX

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€435.40
Price
€440.30
GF Value